Ozempic and Wegovy contain the same molecule, semaglutide. The difference is not in the active ingredient, but in the therapeutic indication and dosages: Ozempic was developed mainly for the treatment of type 2 diabetes, while Wegovy is the formulation approved for the treatment of obesity, with higher doses. For this reason, from the name of the drug it is often possible to understand whether the main goal of therapy is diabetes control or weight reduction. Even though they contain the same molecule, the two drugs are not automatically interchangeable, as they have different authorized indications and therapeutic schemes.
Mounjaro, however, contains tirzepatide, a different molecule. It acts on two receptors involved in the regulation of blood sugar and appetite (GIP and GLP-1). In addition to reducing appetite, it helps many people achieve a sense of satiety more easily after meals, better control hunger throughout the day and further improve blood sugar levels. For this reason, it can lead to greater weight reduction in many patients than semaglutide.
However, this doesn't mean Mounjaro is always the best choice. In patients with type 2 diabetes, semaglutide has solid evidence on cardiovascular benefits and renal protection, gained over many years of clinical studies. Also for tirzepatide the available results are very promising and the evidence continues to strengthen, but the clinical experience is more recent.
In people without diabetes, the choice between semaglutide and tirzepatide is not based solely on effectiveness in weight loss. The doctor evaluates the clinical picture as a whole, considering the degree of obesity, any associated diseases, the tolerability of the treatment, the possible contraindications, the risk of side effects and the long-term therapeutic objectives. In some patients semaglutide is an excellent choice, while in others tirzepatide may offer greater benefit
Side effects are similar for both therapies (nausea, vomiting, diarrhea or constipation) and often depend more on the speed with which the dose is increased than on the drug itself. Furthermore, after suspension it is possible to regain part of the weight lost with both treatments: for this reason it is essential to accompany the therapy with a balanced diet, an adequate intake of proteins and physical activity, so as to encourage weight maintenance and preserve muscle mass.
A frequent mistake is to choose the drug exclusively based on the kilos it allows you to lose. In reality, the ideal treatment is one that allows you to obtain a stable result over time, with good tolerability and without having to be suspended due to unwanted effects. More gradual, but long-lasting, weight loss is often preferable to very rapid weight loss followed by weight regain.
Ultimately, the question should not be "which drug is the strongest?", but "which drug is best suited to my clinical situation?". There is no best drug for everyone: the choice depends on the presence of diabetes, cardiovascular or renal disease, the amount of weight to lose, tolerability, contraindications and the objectives of the therapy. In any case, none of these drugs replace a healthy lifestyle: nutrition, physical activity and medical follow-up remain an integral part of the treatment and are essential to obtain lasting benefits. Greetings, Dr. Lina Travkina